VERX Stock Recent News

Vertex's stock has risen 18% since last December, matching the SPY index, bolstered by promising Phase 2 data for VX-548 in diabetic peripheral neuropathy. Vertex is expanding into gene therapies and other rare disease treatments, recently acquiring Alpine Immune Sciences for $4.9 billion to enhance its rare disease pipeline. Q1 2024 earnings exceeded expectations with a 13% revenue increase, primarily from their cystic fibrosis drug, Trikafta/Kaftrio.

Vertex Pharmaceuticals is working on a therapy to treat diabetes. The latest data about that therapy's performance looks solid.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Vertex Pharmaceuticals recently turned heads with clinical trial results for VX-880, an off-the-shelf cellular therapy for type 1 diabetes patients. Treatment with VX-880 helped patients produce insulin independently and reduced their reliance on daily injections.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented new data from its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). These updated data on 12 patients who received the full dose as a single infusion in Parts B and C of the trial are consistent with previously reported positive.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel [exa-cel]) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented at the annual European Hematology Association (EHA) Congress, confirm the transformative, consistent and durable clinical benefits of CASGEVY over time. CASGEVY is the first and only approved.

KING OF PRUSSIA, Pa., June 12, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc.  (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, announced today the acquisition of tax-specific AI capabilities from Ryan, LLC, an award-winning tax services and software firm, designed to more effectively manage the complexity of tax mapping.

Global biotechnology company Vertex Pharmaceuticals Incorporated (VRTX) is a market-beating outlier stock.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), also known in the European Union and in the U.K. as KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor, were presented at this year's European Cystic Fibrosis Society's (ECFS) 47th European Cystic Fibrosis Conference held June 5-8, 2024, in Glasgow, Scotland. Data from a randomized, double-blind, Phase 3 study.

Biotech companies, like Vertex Pharmaceuticals, benefit from patents, driving consistent growth. Vertex excels in cystic fibrosis treatments and boasts a promising pipeline of new drugs. Vertex's innovation spans pain management and kidney health, with late-stage developments like Vanzacaftor showing significant promise. Its non-opioid painkiller, Suzetrigine, could revolutionize pain management. Vertex's strong financials and growth potential make it a compelling investment. The company's strategic focus on innovation positions it for long-term success.